论文部分内容阅读
目的：探讨紫杉醇联合顺铂化疗对非小细胞肺癌（ non small cell lung cancer,NSCLC）患者机体免疫功能的影响。方法： 45例经病理学或细胞学确诊的 NSCLC患者，采用紫杉醇、顺铂联合化疗方案，应用流式细胞仪检测 CD3、 CD4、 CD8、 CD16、 CD19、 CD25阳性细胞的百分率。结果： NSCLC患者经紫杉醇联合顺铂化疗后 CD4、 CD4/CD8、 CD16、 CD25较化疗前显著升高（ P0.05）；化疗后 CD4、 CD4/CD8、 CD16、 CD25、 CD8、 CD19、 CD3与正常对照组无显著差异（ P >0.05）；鳞癌、腺癌及大细胞癌 3组间化疗前、化疗后各项指标之间无显著性差异（ P >0.05）。结论：紫杉醇联合顺铂化疗可改善机体的免疫功能。
Objective: To investigate the effect of paclitaxel combined with cisplatin chemotherapy on the immune function of patients with non-small cell lung cancer (NSCLC). Methods: Forty-five NSCLC patients diagnosed by pathology or cytology were treated with paclitaxel and cisplatin combined with chemotherapy. The percentage of CD3, CD4, CD8, CD16, CD19, and CD25 positive cells was measured by flow cytometry. RESULTS: CD4, CD4/CD8, CD16, and CD25 were significantly increased in patients with NSCLC after paclitaxel plus cisplatin chemotherapy (P<0.05); after chemotherapy, CD4, CD4/CD8, CD16, CD25, CD8, CD19, CD3 and There was no significant difference in the normal control group (P >0.05). There was no significant difference between the three groups before and after chemotherapy between the squamous cell carcinoma, adenocarcinoma and large cell carcinoma (P > 0.05). Conclusion: Paclitaxel combined with cisplatin chemotherapy can improve the body’s immune function.